1. Murphy K, Murphy BT, Boyce S, Flynn L, Gilgunn S, O’Rourke CJ, Rooney C,
    Stöckmann H, Walsh AL, Finn S, O’Kennedy RJ, O’Leary J, Pennington SR, Perry AS,
    Rudd PM, Saldova R, Sheils O, Shields DC, Watson RW. Integrating biomarkers
    across omic platforms: an approach to improve stratification of patients with
    indolent and aggressive prostate cancer. Mol Oncol. 2018 Sep;12(9):1513-1525.
    doi: 10.1002/1878-0261.12348. Epub 2018 Aug 7. PubMed PMID: 29927052; PubMed
    Central PMCID: PMC6120220.
  2. Rodriguez H, Pennington SR. Revolutionizing Precision Oncology through
    Collaborative Proteogenomics and Data Sharing. Cell. 2018 Apr 19;173(3):535-539.
    doi: 10.1016/j.cell.2018.04.008. PubMed PMID: 29677503; PubMed Central PMCID:
  3. Tyekucheva S, Bowden M, Bango C, Giunchi F, Huang Y, Zhou C, Bondi A, Lis R,
    Van Hemelrijck M, Andrén O, Andersson SO, Watson RW, Pennington S, Finn SP,
    Martin NE, Stampfer MJ, Parmigiani G, Penney KL, Fiorentino M, Mucci LA, Loda M.
    Stromal and epithelial transcriptional map of initiation progression and
    metastatic potential of human prostate cancer. Nat Commun. 2017 Sep 4;8(1):420.
    doi: 10.1038/s41467-017-00460-4. PubMed PMID: 28871082; PubMed Central PMCID:
  4. Tonry C, Armstrong J, Pennington S. Probing the prostate tumour
    microenvironment II: Impact of hypoxia on a cell model of prostate cancer
    progression. Oncotarget. 2017 Feb 28;8(9):15307-15337. doi:
    10.18632/oncotarget.14574. PubMed PMID: 28410543; PubMed Central PMCID:
  5. Tonry C, Armstrong J, Pennington SR. Probing the prostate tumour
    microenvironment I: impact of glucose deprivation on a cell model of prostate
    cancer progression. Oncotarget. 2017 Feb 28;8(9):14374-14394. doi:
    10.18632/oncotarget.14605. PubMed PMID: 28086232; PubMed Central PMCID:
  6. Staunton L, Tonry C, Lis R, Espina V, Liotta L, Inzitari R, Bowden M, Fabre A,
    O’Leary J, Finn SP, Loda M, Pennington SR. Pathology-Driven Comprehensive
    Proteomic Profiling of the Prostate Cancer Tumor Microenvironment. Mol Cancer
    Res. 2017 Mar;15(3):281-293. doi: 10.1158/1541-7786.MCR-16-0358. Epub 2017 Jan 5.
    PubMed PMID: 28057717.
  7. Leacy E, Finn S, Pennington SR. Need for biomarkers in active surveillance of prostate cancer. Oncology News. Includes ‘View from the Clinic – A Patient’s Perspective’ 2016.
  8. Tonry CL, Leacy E, Raso C, Finn SP, Armstrong J, Pennington SR. The Role of
    Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical
    Decision Making in Prostate Cancer. Diagnostics (Basel). 2016 Jul 18;6(3). pii:
    E27. doi: 10.3390/diagnostics6030027. Review. PubMed PMID: 27438858; PubMed
    Central PMCID: PMC5039561.
  9. Percy AJ, Byrns S, Pennington SR, Holmes DT, Anderson NL, Agreste TM, Duffy
    MA. Clinical translation of MS-based, quantitative plasma proteomics: status,
    challenges, requirements, and potential. Expert Rev Proteomics. 2016
    Jul;13(7):673-84. doi: 10.1080/14789450.2016.1205950. Epub 2016 Jul 8. Review.
    PubMed PMID: 27341553.
  10. Staunton L, Tonry C, Lis R, Finn S, O Leary J, Loda M, Bowden M, Pennington
    SR. Profiling the tumor microenvironment proteome in prostate cancer using laser
    capture microdissection coupled to LC⿿MS⿿A technical report. EuPA Open Proteom.
    2015 Dec 29;10:19-23. doi: 10.1016/j.euprot.2015.11.001. eCollection 2016 Mar.
    PubMed PMID: 29900095; PubMed Central PMCID: PMC5988569.
  11. Hernández B, Parnell A, Pennington SR. Why have so few proteomic biomarkers
    “survived” validation? (Sample size and independent validation considerations).
    Proteomics. 2014 Jul;14(13-14):1587-92. doi: 10.1002/pmic.201300377. Epub 2014
    May 16. PubMed PMID: 24737731.
  12. Oon SF, Pennington SR, Fitzpatrick JM, Watson RW. Biomarker research in
    prostate cancer–towards utility, not futility. Nat Rev Urol. 2011
    Mar;8(3):131-8. doi: 10.1038/nrurol.2011.11. Review. PubMed PMID: 21394176.